Pfizer, a US pharmaceutical company, announced on Tuesday that it would not sell Corona 19 vaccine cheaper than in the United States to developed countries.

Pfizer CEO Alberta Bulla told a conference call on the day, "All countries in the developed world will not receive the same amount of vaccine at a lower price than the United States," Reuters reported.

This means that Pfizer may be able to set prices like this or higher for other developed countries based on the vaccine delivery price recently signed by the US government.

Pfizer, which is co-developing Corona19 vaccine with Germany's Bioentech, has signed an agreement with the US Department of Health and Human Services on the 22nd to supply 100 million doses of Corona19 vaccine for a total of $1.9 billion.

This vaccine is equivalent to 50 million inoculations in that it is likely to form antibodies when administered twice per person, Reuters analyzed.

The cost of inoculation per person is $39, which is about 47,000 won, which is not much different from the flu vaccine price.

When the corona19 pandemic ends, the price of the vaccine may change, Pfizer said.

The CEO said it is discussing with the European Union a number of EU member states about vaccine supply.

"We're in negotiations with the EU, because it's much easier to do," he said. "But we have a wide range of dialogue with multiple member countries in case we fail to reach an agreement with the EU."

CEO Bulla also criticized President Donald Trump's administrative order for drug price cuts last week and criticized it as "an action that distracts the minds when the pharmaceutical industry needs to focus entirely on developing corona19 vaccines and treatments."

He added that Pfizer's plans to expand the U.S. market could be reconsidered if an administrative order were implemented.

On the previous day, Pfizer and Bioentech entered a phase 3 clinical trial in Corona 19 vaccine.

US pharmaceutical company Modena also announced the start of a phase 3 trial of the same scale.

(Photo = Getty Image Korea)